TRADE POLICY | 2026-09-10

USTR Section 301 Investigation Into German Pharmaceutical Pricing: What California Life-Sciences Importers Need to Know Before the September 22, 2026 Hearing

A California trade and customs analysis of the USTR Section 301 investigation into German pharmaceutical underpayment, the September 22, 2026 public hearing, and the retaliatory tariff exposure facing San Diego and Bay Area biopharma importers

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

The Office of the U.S. Trade Representative has opened a Section 301 investigation that could reshape the cost of doing business for California life-sciences companies that source from Germany. Initiated on June 18, 2026 and published in the Federal Register on June 24, 2026, the investigation targets what USTR describes as Germany's persistent underpayment for innovative pharmaceutical products. USTR is examining German pricing rules that condition the confidentiality of manufacturer prices on

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301